PMID- 35855199
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220721
IS  - 2587-0831 (Print)
IS  - 2587-0831 (Electronic)
VI  - 18
IP  - 3
DP  - 2022 Jul
TI  - Association Between GATA3 and Histopathological and Immunohistochemical 
      Parameters in Early-Infiltrating Breast Carcinomas.
PG  - 229-234
LID - 10.4274/ejbh.galenos.2022.2022-3-9 [doi]
AB  - OBJECTIVE: This study evaluated the frequency of GATA-binding protein 3 (GATA3) 
      expression in early breast cancer and its relationship with histopathological and 
      immunohistochemical parameters. MATERIALS AND METHODS: GATA3 was analysed by 
      immunohistochemistry in histological sections of tumors from 105 female patients, 
      with histological diagnosis of invasive breast carcinoma (BC), at clinical stages 
      I, II and IIIA, who underwent primary surgical treatment. GATA3 nuclear 
      expression was determined as the percentage of positive tumor cells and further 
      categorized as high (positive expression in more than 95% of cells) or non-high 
      (negative or low positive expression in up to 95% of tumor cells). GATA3 
      expression was analysed according to the patient age, tumor and node pathological 
      stage, histological type, histological and nuclear grade, lymphovascular 
      invasion, and estrogen receptor (ER), progesterone receptor (PR), androgen 
      receptor (AR), human epidermal growth factor 2 (HER2) status, and Ki-67 
      expression. RESULTS: GATA3 expression was positive in 103 cases (98.1%). High 
      expression was significantly associated with low histological and nuclear grade, 
      positive hormonal receptors, and less proliferative activity based on Ki-67 
      expression. A prominent feature was that 94.7% of the ER-positive/HER2-negative 
      cases presented high-GATA3 expression, as 94.0% of the tumors showing high-GATA3 
      were ER-positive. In ER-negative/HER2-positive or ER-negative/HER2- negative, 
      high-GATA3 was present in 25% while 75% were non-high-GATA3 compared with 
      ER-positive/HER2- negative (4.1%) and ER-positive/HER2-positive (20%). 
      Proliferative activity in triple-negative breast cancer tended to be higher among 
      tumors with low-GATA3, irrespective of AR expression. In the group of 
      ER-positive/HER2-negative tumors only three cases were low-GATA3 (85% and 80%), 
      both with high proliferative activity. CONCLUSION: High GATA3 expression is 
      associated with favorable histopathologic and immunohistochemical BC prognostic 
      factors.
CI  - (c)Copyright 2022 by the the Turkish Federation of Breast Diseases Societies / 
      European Journal of Breast Health published by Galenos Publishing House.
FAU - de Medeiros Souza, Priscila
AU  - de Medeiros Souza P
AUID- ORCID: 0000-0002-3104-8133
AD  - Discipline of Experimental Physiopathology, University of Sao Paulo School of 
      Medicine, Sao Paulo, Brazil.
FAU - Carvalho, Filomena Marino
AU  - Carvalho FM
AUID- ORCID: 0000-0002-5838-3636
AD  - Department of Pathology, University of Sao Paulo School of Medicine, Sao Paulo, 
      Brazil.
FAU - Aguiar, Fernando N
AU  - Aguiar FN
AUID- ORCID: 0000-0003-3602-9019
AD  - Cancer Institute of the State of Sao Paulo, Sao Paulo, Brazil.
FAU - Gagliato, Debora
AU  - Gagliato D
AUID- ORCID: 0000-0001-7480-0674
AD  - Department of Oncology, Beneficencia Portuguesa Hospital, Sao Paulo, Brazil.
FAU - de Barros, Alfredo Carlos Simoes Dornellas
AU  - de Barros ACSD
AUID- ORCID: 0000-0003-2535-3040
AD  - Discipline of Experimental Physiopathology, University of Sao Paulo School of 
      Medicine, Sao Paulo, Brazil.
AD  - Department of Mastology, Beneficencia Portuguesa Hospital, Sao Paulo, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20220701
PL  - Turkey
TA  - Eur J Breast Health
JT  - European journal of breast health
JID - 101709357
PMC - PMC9255655
OTO - NOTNLM
OT  - Breast cancer
OT  - GATA3 expression
OT  - histopathology
OT  - immunohistochemistry
COIS- Conflict of Interest: No conflict of interest was declared by the authors.
EDAT- 2022/07/21 06:00
MHDA- 2022/07/21 06:01
PMCR- 2022/07/01
CRDT- 2022/07/20 02:12
PHST- 2022/03/25 00:00 [received]
PHST- 2022/06/04 00:00 [accepted]
PHST- 2022/07/20 02:12 [entrez]
PHST- 2022/07/21 06:00 [pubmed]
PHST- 2022/07/21 06:01 [medline]
PHST- 2022/07/01 00:00 [pmc-release]
AID - 52373 [pii]
AID - 10.4274/ejbh.galenos.2022.2022-3-9 [doi]
PST - epublish
SO  - Eur J Breast Health. 2022 Jul 1;18(3):229-234. doi: 
      10.4274/ejbh.galenos.2022.2022-3-9. eCollection 2022 Jul.